最新ニュース Mustang Bio (NASDAQ:MBIO) 株価情報

Mustang Bio

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Mustang Bio Inc

Needham analyst Scott Berg reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and maintains $400 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Salesforce, Maintains $400 Price Target

Barclays analyst Brandon Oglenski maintains Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) with a Overweight and lowers the price target from $62 to $55.

Barclays Maintains Overweight on Alaska Air Gr, Lowers Price Target to $55

TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders.
The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide ("PEA"). This innovative combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment.

CMND

SPRC

SciSparc, Clearmind Collaboration Leads To Filing Of International Patent Application For Proprietary Treatment Targeting Anorexia, Bulimia And Other Eating Disorders

Needham analyst Joshua Reilly reiterates Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) with a Buy and maintains $30 price target.

VRNT

Needham Reiterates Buy on Verint Systems, Maintains $30 Price Target

Barclays analyst Christine Cho maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Overweight and lowers the price target from $58 to $51.

ENPH

Barclays Maintains Overweight on Enphase Energy, Lowers Price Target to $51

The United States can explore multiple options to establish a domestic supply chain for rare earths within the next five years to replace China&#8217;s global monopoly. However, industry experts warn that the process is fraught with challenges.
What Happened:&nbsp;The U.S. possesses the majority&nbsp;of the 17 rare earth&nbsp;elements and 50 critical minerals. Colorado School of Mines economist Ian Lange said, "I'm on the optimistic side," noting that substitutes exist for the seven restricted rare earths and some manufacturers believe they can manage without them, <a href="https://www.theepochtimes.com/article/us-can-produce-rare-earths-if-china-stops-exports-but-theres-a-catch-5843935">reported </a>The Epoch Times.
On April 2, President Trump instructed Commerce Secretary Howard Lutnick to recommend strategies within 180 days for how the federal government can support the development of a domestic rare earth supply chain. Economist Antonio Graceffo believes the industry will respond if steps like permit reform, deregulation, and public-private incentives are implemented.
The two main rare earth operators in the U.S. are Australia&#8217;s Lynas Rare Earths and MP Materials Corp., based in Las Vegas. Both play a crucial role in processing rare earths for the Department of Defense, which is currently halfway through a five-year plan to establish a "sustainable mine-to-magnet supply chain" by 2027.
According to analyst Lifton, a 145% tariff on China's exports of processed rare earth minerals to the U.S. would make such trade economically unviable. Graceffo noted that there are "tons of solutions" to establish a domestic rare earth supply chain, including ongoing talks with Ukraine. 
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/44916608/mark-zuckerbergs-wife-priscilla-chans-tuition-free-school-to-shutdown-50-million-support-pledged-for-transition" target="_blank" rel="noreferrer noopener">Mark Zuckerberg&#8217;s Wife Priscilla Chan&#8217;s Tuition-Free School To Shutdown, $50 Million Support Pledged For Transition &#8211; Benzinga</a>
Why It Matters: The move to establish a domestic supply chain comes amid rising tensions with China, which has a dominant position in the global rare earths market and has <a href="https://www.benzinga.com/25/04/44650952/china-restricts-rare-earth-exports-to-us-as-part-of-tariff-retaliation">restricted the export </a>of seven critical rare earth minerals. On Thursday, President Donald Trump signed an executive order to fast-track deep-sea mining, seeking to offset China&#8217;s dominance in critical mineral supply chains, as reported by CNBC.
Furthermore, American Resources Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) has recently expanded its <a href="https://www.benzinga.com/25/04/44901061/arec-doubles-down-on-rare-earths-supercharges-production-in-just-3-weeks">operational </a>equipment to meet the rising demand for domestically sourced rare earth oxides. This expansion indicates a growing focus on the domestic production of rare earths.
Also, USA Rare Earth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) is focused on establishing "one of the largest" rare earth magnet manufacturing facilities in the U.S., aiming to become a top supplier of high-value rare earth magnets and critical minerals.
However, the challenges in refining and processing these critical minerals remain a significant hurdle. Mining and refining projects can&nbsp;take 10 to 20 years&nbsp;to get approved, say experts. Moreover, the country lacks the industrial capacity to refine these&nbsp;into processed metals and magnets,&nbsp;according to&nbsp;Melissa "Mel" Sanderson, board member of American Rare Earths and co-chair of the Critical Minerals Institute.
USA Rare Earth stock surged 97.17% over the past month. On Thursday, it closed 21.6% higher at $13.23, as per <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/45002083/court-documents-reveal-charges-filed-against-dc-tesla-vandalism-suspect-report" target="_blank" rel="noreferrer noopener">DC Man Arrested For Vandalizing Tesla Cars In &#8216;Tesla Takedown&#8217; Protest, Faces June Court Date</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

AREC

USAR

US Has 'Tons Of Solutions' To Secure Rare Earth Production If China Halts Exports, Experts Say, But Warn Of Significant Challenges

Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30.
"At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms."
Abstracts accepted for presentation at AACR include:
Mini Symposium
INCB177054
INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #3789.))
Poster Presentations
INCA33890
INCA33890 Increases CD8+ T-Cell Effector Function Compared with pembrolizumab as Assessed by Single-Cell RNA Sequencing in Human PD-1xTGFβR2 Knock-In Mouse Model (Session Title: Immune Fitness and Metabolic Regulation of Cancer Immunity​. April 29, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT). Abstract #4861.))
INCA33890, a Bispecific Antibody Targeting PD-1 and TGFβR2, Shows Enhanced Immune Responses in Models of Ovarian Cancer (Session Title: Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators. April 29, 3:00 p.m. – 6:00 p.m. ET (2:00 – 5:00 p.m. CT). Abstract #6074.))
PD-1xTGFβR2 Bispecific Biclonics&#xAE; Antibody INCA33890 Augments Human T-Cell Effector Functions In Vitro and Ex Vivo (Session Title: Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators​. April 29, 3:00 p.m. – 6:00 p.m. ET (2:00 – 5:00 p.m. CT). Abstract #6071.))
INCB057643
INCB057643, a Bromodomain and Extra-Terminal (BET) Protein Inhibitor, Improved Bone Marrow Function and Shifted Megakaryopoiesis to Erythropoiesis in Patients with Myeloproliferative Neoplasms (MPNs) (Session Title: Molecular Genetics and Epigenetics of Tumors​. April 30, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT). Abstract #7188.))
Novel Role of INCB057643, a Bromodomain and Extra-Terminal (BET) Protein Inhibitor, in Myeloid Cell Regulation and Immunosuppressive Tumor Environment Remodeling in Myelofibrosis (MF) (Session Title: Molecular Genetics and Epigenetics of Tumors​. April 30, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT). Abstract #7184.))
Association of Cyclin E1 Expression with Genomic Instability in Ovarian Cancer (Session Title: Origins and Mechanisms of Genomic Instability​. April 28, 3:00 p.m. – 6:00 p.m. ET (2:00 – 5:00 p.m. CT). Abstract #2846.))
About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation &amp; Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

Biotech

General

INCY

Incyte Announces IT Will Present New Early-Stage Data From Its Oncology Portfolio At American Association Of Cancer Research Annual Meeting 2025 In Chicago, IL, From April 25–30

Trinet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) reported quarterly earnings of $1.99 per share which beat the analyst consensus estimate of $1.60 by 24.37 percent. This is a 7.87 percent decrease over earnings of $2.16 per share from the same period last year. The company reported quarterly sales of $1.29 billion which beat the analyst consensus estimate of $1.28 billion by 0.97 percent. This is a 2.22 percent increase over sales of $1.26 billion the same period last year.

Earnings

Earnings Beats

TNET

Trinet Group Q1 Adj. EPS $1.99 Beats $1.60 Estimate, Sales $1.29B Beat $1.28B Estimate

Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.08 by 12.5 percent. This is a 18.18 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $10.16 million which beat the analyst consensus estimate of $9.90 million by 2.64 percent. This is a 4.84 percent decrease over sales of $10.68 million the same period last year.

OXSQ

Oxford Square Cap Q1 EPS $0.09 Beats $0.08 Estimate, Sales $10.16M Beat $9.90M Estimate

GNTX

Gentex Q1 EPS $0.42, Inline, Sales $576.8M Beat $571.97M Estimate

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $69.4, a high estimate of $75.00, and a low estimate of $58.00. This current average has increased by 1.46% from the previous average price target of $68.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582501_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Halozyme Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $58.00&#x7C;$55.00 &#x7C; 
&#x7C;Robert Wasserman &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $72.00&#x7C;$70.00 &#x7C; 
&#x7C;Mitchell Kapoor &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $70.00&#x7C;$70.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Halozyme Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Halozyme Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Halozyme Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Halozyme Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HALO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Halozyme Therapeutics analyst ratings.</a>
<h2>Discovering Halozyme Therapeutics: A Closer Look</h2>
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
<h3>Breaking Down Halozyme Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Halozyme Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 29.55% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 45.98%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Halozyme Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 33.56% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Halozyme Therapeutics's ROA excels beyond industry benchmarks, reaching 6.55%. This signifies efficient management of assets and strong financial health.
Debt Management: Halozyme Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 4.14. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HALO

Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings)

Across the recent three months, 4 analysts have shared their insights on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00, and a low estimate of $314.00. This current average represents a 5.57% decrease from the previous average price target of $372.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582487_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive United Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tiago Fauth &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $314.00&#x7C;$395.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $355.00&#x7C;$357.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;B of A Securities &#x7C;Maintains &#x7C;Neutral &#x7C; $314.00&#x7C;$314.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $425.00&#x7C;$425.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into United Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Delving into United Therapeutics's Background</h2>
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
<h3>United Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining United Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.72% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 40.94%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): United Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 4.8%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): United Therapeutics's ROA excels beyond industry benchmarks, reaching 4.16%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UTHR

Demystifying United Therapeutics: Insights From 4 Analyst Reviews

Providing a diverse range of perspectives from bullish to bearish, 26 analysts have published ratings on Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $196.69, with a high estimate of $229.00 and a low estimate of $159.00. Experiencing a 7.19% decline, the current average is now lower than the previous average price target of $211.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582474_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Alphabet is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ken Gawrelski &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $175.00&#x7C;$167.00 &#x7C; 
&#x7C;Barton Crockett &#x7C;Rosenblatt &#x7C;Lowers &#x7C;Neutral &#x7C; $189.00&#x7C;$205.00 &#x7C; 
&#x7C;Mark Kelley &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $192.00&#x7C;$225.00 &#x7C; 
&#x7C;Brad Erickson &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $200.00&#x7C;$200.00 &#x7C; 
&#x7C;Brian Nowak &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $185.00&#x7C;$210.00 &#x7C; 
&#x7C;Brian Pitz &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $200.00&#x7C;$230.00 &#x7C; 
&#x7C;Youssef Squali &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $200.00&#x7C;$220.00 &#x7C; 
&#x7C;Deepak Mathivanan &#x7C;Cantor Fitzgerald &#x7C;Lowers &#x7C;Neutral &#x7C; $159.00&#x7C;$200.00 &#x7C; 
&#x7C;Laura Martin &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $178.00&#x7C;$178.00 &#x7C; 
&#x7C;Gil Luria &#x7C;DA Davidson &#x7C;Lowers &#x7C;Neutral &#x7C; $160.00&#x7C;$200.00 &#x7C; 
&#x7C;Ronald Josey &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $195.00&#x7C;$229.00 &#x7C; 
&#x7C;Thomas Champion &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $185.00&#x7C;$208.00 &#x7C; 
&#x7C;James Lee &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $205.00&#x7C;$230.00 &#x7C; 
&#x7C;Doug Anmuth &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $180.00&#x7C;$220.00 &#x7C; 
&#x7C;Ken Gawrelski &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $167.00&#x7C;$184.00 &#x7C; 
&#x7C;Brent Thill &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $200.00&#x7C;$235.00 &#x7C; 
&#x7C;Deepak Mathivanan &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Neutral &#x7C; $200.00&#x7C;$200.00 &#x7C; 
&#x7C;Rohit Kulkarni &#x7C;Roth MKM &#x7C;Maintains &#x7C;Buy &#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Barton Crockett &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Neutral &#x7C; $205.00&#x7C;$205.00 &#x7C; 
&#x7C;Justin Patterson &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $202.00&#x7C;$220.00 &#x7C; 
&#x7C;Thomas Champion &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $208.00&#x7C;$210.00 &#x7C; 
&#x7C;Doug Anmuth &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $220.00&#x7C;$232.00 &#x7C; 
&#x7C;Ronald Josey &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $229.00&#x7C;$232.00 &#x7C; 
&#x7C;Brian Nowak &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $210.00&#x7C;$215.00 &#x7C; 
&#x7C;Laura Martin &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $225.00&#x7C;$225.00 &#x7C; 
&#x7C;Laura Martin &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $225.00&#x7C;$210.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alphabet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alphabet compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Alphabet's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Alphabet's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alphabet analyst ratings.</a>
<h2>All You Need to Know About Alphabet</h2>
Alphabet is a holding company that wholly owns internet giant Google. The California-based company derives slightly less than 90% of its revenue from Google services, the vast majority of which is advertising sales. Alongside online ads, Google services houses sales stemming from Google's subscription services (YouTube TV, YouTube Music among others), platforms (sales and in-app purchases on Play Store), and devices (Chromebooks, Pixel smartphones, and smart home products such as Chromecast). Google's cloud computing platform, or GCP, accounts for roughly 10% of Alphabet's revenue with the firm's investments in up-and-coming technologies such as self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) making up the rest.
<h3>Financial Milestones: Alphabet's Journey</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Alphabet's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.77% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.
Net Margin: Alphabet's net margin is impressive, surpassing industry averages. With a net margin of 27.51%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Alphabet's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Alphabet's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: Alphabet's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GOOGL

Breaking Down Alphabet: 26 Analysts Share Their Views

Canaccord Genuity analyst Brian McNamara maintains Rollins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) with a Hold and raises the price target from $49 to $50.

Canaccord Genuity Maintains Hold on Rollins, Raises Price Target to $50

Ratings for Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) were provided by 16 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $37.31, with a high estimate of $50.00 and a low estimate of $28.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 15.57%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582454_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Dow among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Frank Mitsch &#x7C;Fermium Research &#x7C;Maintains &#x7C;Buy &#x7C; $35.00&#x7C;$35.00 &#x7C; 
&#x7C;Michael Leithead &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $32.00&#x7C;$38.00 &#x7C; 
&#x7C;Steve Byrne &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $28.00&#x7C;$44.00 &#x7C; 
&#x7C;Michael Sison &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $35.00&#x7C;$40.00 &#x7C; 
&#x7C;Joshua Spector &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $29.00&#x7C;$41.00 &#x7C; 
&#x7C;Charles Neivert &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $37.00&#x7C;$46.00 &#x7C; 
&#x7C;Michael Sison &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $40.00&#x7C;$50.00 &#x7C; 
&#x7C;Patrick Cunningham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $31.00&#x7C;$39.00 &#x7C; 
&#x7C;Jeffrey Zekauskas &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $31.00&#x7C;$40.00 &#x7C; 
&#x7C;Michael Leithead &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $38.00&#x7C;$44.00 &#x7C; 
&#x7C;Charles Neivert &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $46.00&#x7C;$53.00 &#x7C; 
&#x7C;Jeffrey Zekauskas &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $40.00&#x7C;$47.00 &#x7C; 
&#x7C;Arun Viswanathan &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $38.00&#x7C;$41.00 &#x7C; 
&#x7C;Michael Sison &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $50.00&#x7C;$55.00 &#x7C; 
&#x7C;Vincent Andrews &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $43.00&#x7C;$46.00 &#x7C; 
&#x7C;Michael Leithead &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $44.00&#x7C;$48.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dow. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Dow compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Dow's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Dow's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DOW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dow analyst ratings.</a>
<h2>Delving into Dow's Background</h2>
Dow Inc is a diversified chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a key producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets. The Company conducts its operations through six businesses, which are organized into segments, such as Packaging &amp; Specialty Plastics, Industrial Intermediates &amp;and Infrastructure and Performance Materials and Coatings. Packaging and Specialty.
<h3>Understanding the Numbers: Dow's Finances</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Dow's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -2.03%. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Dow's net margin excels beyond industry benchmarks, reaching -0.54%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Dow's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.31%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Dow's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.1%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.02, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Dow In The Eyes Of 16 Experts

In the preceding three months, 13 analysts have released ratings for Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Williams-Sonoma, revealing an average target of $188.23, a high estimate of $230.00, and a low estimate of $131.00. This current average has increased by 0.58% from the previous average price target of $187.15. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582439_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Williams-Sonoma among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Bradley Thomas &#x7C;Keybanc &#x7C;Maintains &#x7C;Overweight &#x7C; $181.00&#x7C;$181.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $220.00&#x7C;$220.00 &#x7C; 
&#x7C;Oliver Wintermantel &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $175.00&#x7C;$180.00 &#x7C; 
&#x7C;Zachary Fadem &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $170.00&#x7C;$195.00 &#x7C; 
&#x7C;Jonathan Matuszewski&#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $208.00&#x7C;$226.00 &#x7C; 
&#x7C;Seth Basham &#x7C;Wedbush &#x7C;Lowers &#x7C;Neutral &#x7C; $170.00&#x7C;$190.00 &#x7C; 
&#x7C;Christopher Horvers &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $168.00&#x7C;$153.00 &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $165.00&#x7C;$140.00 &#x7C; 
&#x7C;Simeon Gutman &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $185.00&#x7C;$195.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Outperform &#x7C; $220.00&#x7C;$230.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $230.00&#x7C;$230.00 &#x7C; 
&#x7C;Seth Sigman &#x7C;Barclays &#x7C;Raises &#x7C;Underweight &#x7C; $131.00&#x7C;$123.00 &#x7C; 
&#x7C;Kate McShane &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Neutral &#x7C; $224.00&#x7C;$170.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Williams-Sonoma. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Williams-Sonoma compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Williams-Sonoma's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Williams-Sonoma's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Williams-Sonoma analyst ratings.</a>
<h2>Get to Know Williams-Sonoma Better</h2>
With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas. Namesake Williams-Sonoma (154 stores) offers high-end cooking essentials, while Pottery Barn (184) provides casual home accessories. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (11) offers lighting and house parts. Brand extensions include Pottery Barn Kids and Pottery Barn Teen (46) as well as Mark &amp; Graham and GreenRow. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
<h3>Understanding the Numbers: Williams-Sonoma's Finances</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Williams-Sonoma displayed positive results in 3M. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 8.04%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Williams-Sonoma's net margin is impressive, surpassing industry averages. With a net margin of 15.63%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Williams-Sonoma's ROE stands out, surpassing industry averages. With an impressive ROE of 19.01%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Williams-Sonoma's ROA stands out, surpassing industry averages. With an impressive ROA of 7.5%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Williams-Sonoma's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.63.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Williams-Sonoma Through 13 Analysts

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Hasbro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $78.25, with a high estimate of $84.00 and a low estimate of $72.00. Observing a 2.52% increase, the current average has risen from the previous average price target of $76.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582426_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Hasbro. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;James Hardiman &#x7C;Citigroup &#x7C;Announces &#x7C;Buy &#x7C; $72.00&#x7C;- &#x7C; 
&#x7C;Linda Bolton Weiser &#x7C;DA Davidson &#x7C;Raises &#x7C;Neutral &#x7C; $75.00&#x7C;$73.00 &#x7C; 
&#x7C;Megan Alexander &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $84.00&#x7C;$88.00 &#x7C; 
&#x7C;Eric Handler &#x7C;Roth MKM &#x7C;Raises &#x7C;Buy &#x7C; $82.00&#x7C;$68.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hasbro. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hasbro compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hasbro's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hasbro analyst ratings.</a>
<h2>Delving into Hasbro's Background</h2>
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and since has pruned noncore lines from the tie-up. Furthermore, the addition of Dungeons &amp; Dragons Beyond in 2022, offers the firm access to 19 million digital tabletop players.
<h3>Unraveling the Financial Story of Hasbro</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Challenges: Hasbro's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -14.53%. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.81%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.51%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 2.95, Hasbro faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Hasbro

WIIM

SAIA

Saia shares are trading lower following a Q1 EPS and revenue miss.

Ponce Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDLB#NASDAQ">PDLB</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.12 by 108.33 percent. This is a 127.27 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $24.58 million which beat the analyst consensus estimate of $22.20 million by 10.74 percent. This is a 19.75 percent increase over sales of $20.53 million the same period last year.

PDLB

Ponce Finl Gr Q1 EPS $0.25 Beats $0.12 Estimate, Sales $24.58M Beat $22.20M Estimate

Canaccord Genuity analyst George Gianarikas maintains LSI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>) with a Buy and lowers the price target from $26 to $22.

LYTS

Canaccord Genuity Maintains Buy on LSI Industries, Lowers Price Target to $22

Financing

Press Releases

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Health Care

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Announces Reverse Stock Split

IPOs

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

MBIO

Aditxt

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Galecto

Genprex

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

NuCana

Oragenics

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Synaptogenix

Tharimmune

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Xenetic Biosciences

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Mustang Bio

ニュース

最新ニュース Mustang Bio (NASDAQ:MBIO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル